PATENT 0471-0286PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

FUSENIG, Norbert E. et al.

Appl. No.:

NEW

Group:

Filed:

July 7, 2004

Examiner:

For:

BIOMATERIALS BASED ON HYALURONIC ACID FOR THE ANTI-ANGIOGENIC THERAPY IN THE

TREATMENT OF TUMOURS

INFORMATION DISCLOSURE STATEMENT (SUBMISSION CONCURRENT WITH THE FILING OF A NEW PATENT APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 July 7, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a.	This application was filed before June 30, 2003.
	Accordingly, submitted herewith is a legible copy
	of (i) each U.S. and foreign patent; (ii) each
	publication or that portion which caused it to be
	listed; and (iii) all other information or that
	portion which caused it to be listed.

b.			plication					
			2003. A					
			and pate					
			are not					
	•	patent d	ocuments .	and no	n-patent	lit	erature	are
		included.						

c. A This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER

The following additional information is provided for the Examiner's consideration.

Docket No. 0471-0286PUS1

FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

LRS/lmt

0471-0286PUS1

Attachment(s):

Fee

Respectfully submitted, BIRCH, STEWART, KOZASCH & BIRCH, LLP R. Svensson, #30,330 P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000 Form PTO-1449(s) Documents Foreign Search Report Other:

(Rev. 02/12/2004)

ATTY. DOCKET NO. Form PTO-1449 APPLICATION NO. NW0/50103 0471-0286PUS1 INFORMATION DISCLOSURE CITATION APPLICANT FUSENIG, Norbert E. et al. IN AN APPLICATION (Use several sheets if necessary) FILING DATE July 7, 2004 U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER FILING DATE
IF APPROPRIATE Kind DATE NAME US 4,851,521 Α 1989-07-25 DELLA VALLE ET AL. US 5,520,916 Α 1996-05-28 CALLEGARO ET AL. US US US US US US US US FOREIGN PATENT DOCUMENTS Office DOCUMENT Kind DATE COUNTRY TRANSLATION NUMBER ΝО 0341745 EP Α 1989-11-15 EP. 0466300 EP 1992-01-15 Α EP WO 99/61080 Α 1999-12-02 WO 00/01733 2000-01-13 WO Α WO 00/54762 WO Α 2000-09-21 WO WO 00/57896 Α 2000-10-05 WO WO 02/18448 2002-03-07 Α WO OW. 02/18450 A 2002-03-07 WO WO 02/41877 2002-05-30 WO OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. TONELLO et al. "In vitro reconstruction of human dermal equivalent enriched with endothelial cells" Biomaterials, Vol. 24, No. 7, 7 March 2003, pp. 1205-1211 GLASS et al. "A three-dimensional cell attachment matrix created by cross-linking RGD peptide modified hyaluronic acid" Journal of Cellular Biochemistry, Suppl. 19A, 5 January 1996, p. 178 LUO et al. "Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery" Journal of Controlled Release, Vol. $\acute{ exttt{69}}$, No. 1, 3 October 2000, pp. 169- $\acute{ exttt{1}}$ 84 CORADINI et al. "Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line" International Journal of Cancer, Vol. 81, No. 3, 5 May 1999, pp. 411-416 EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.